Secondary surgery in germ cell tumors - When and how extensively should it be performed?

World Journal of Urology

Volumn 22, Issue 1, 2004, Pages 37-40

  Foster, Richard S ^a   Beck, Stephen ^a   Bihrle, Richard ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Postchemotherapy; RPLND; Surgery; Template; Testis cancer

Indexed keywords

GERM CELL TUMOR; HUMAN; LYMPHADENECTOMY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; REOPERATION; RETROPERITONEUM; REVIEW; TIME;

COMBINED MODALITY THERAPY; GERMINOMA; HUMANS; LYMPH NODE EXCISION; REOPERATION; RETROPERITONEAL SPACE; TIME FACTORS;

EID: 4344628469     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0402-3     Document Type: Review

References (18)

1. Debono DJ, Heilman DK, Einhorn LH et al. (1997) Decision analysis for avoiding post chemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455
2. Fossa S, Aass N, Ous S et al. (1989) Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 142:1239
3. Weissbach L, Bussar-Maatz R, Fletchtner H et al (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Eur Urol 37:582
4. Loehrer PJ, Johnson D, Elson P et al. (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470
5. Oldenburg J, Alfsen GC, Lien HH et al (2003) Post chemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor mass. J Clin Oncol 21:3310
6. Fossa SD, Qvist H, Stenwig AE et al. (1992) Is post chemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10:569
7. Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8:1683
8. Baniel J, Foster RS, Rowland RG et al. (1995) Complications of post chemotherapy retroperitoneal lymph node dissection. J Urol 153:976
9. Mosharafa A, Foster RS, Koch MO et al. (2003) Complications of post chemotherapy retroperitoneal lymph node dissection. J Urol 169:930A
10. Coogan CL, Foster RS, Rowland RG et al. (1997) Post chemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy only. Urology 50:957
11. Motzer R, Bosl G, Heelan RT et al. (1987) Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 5:1065
12. Schultz SM, Einhorn LH, Conces DJ et al. (1989) Management of post chemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7:1497
13. DeSantis M, Bokemeyer C, Becherer A et al (2001) Predictive impact of 2-fluoro-2-deoxy-D-glucose positron emission tomography for residual post chemotherapy masses in patients with bulky seminoma. J Clin Oncol 19:3740
14. Donohue JP, Rowland RG (1989) The role of surgery in advanced testicular cancer. Cancer 63:440
15. Donohue JP, Thornhill JA, Foster RS et al. (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149:237
16. Wahle GR, Foster RS, Bihrle R et al. (1994) Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J Urol 152:428
17. Wood DP, Herr HW, Heller G et al. (1992) Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148:1812
18. Feuer EJ, Sheinfeld J, Bosl GJ. (1999) Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91:816